Clinical Trials Using Cetuximab

Clinical trials are research studies that involve people. The clinical trials on this list are studying Cetuximab. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 26-40 of 40

  • Cetuximab after Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer

    This phase II trial studies how well cetuximab after immunotherapy with PD-1 inhibitors work in treating patients with head and neck squamous cell cancer. Cetuximab is an antibody (protein structure) that blocks receptors on cancer cells, called EGFR receptors, that favor the growth and multiplication of the cancer cells. Giving cetuximab may work better when given in patients who stopped responding to immunotherapy or who had to stop immunotherapy because of toxicity.
    Location: Wake Forest University Health Sciences, Winston-Salem, North Carolina

  • Radiation Therapy and Cisplatin with or without Cetuximab in Treating Patients with HPV Positive, KRAS-Variant Stage III-IV Oropharyngeal Squamous Cell Carcinoma

    This phase II trial studies how well radiation therapy and cisplatin with or without cetuximab works in treating patients with human papillomavirus (HPV) positive, KRAS-variant stage III-IV oropharyngeal squamous cell carcinoma. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Cetuximab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Giving radiation therapy, cisplatin, and cetuximab may work better in treating patients with HPV positive, KRAS-variant oropharyngeal squamous cell carcinoma compared to radiation therapy and cisplatin alone.
    Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

  • sEphB4-HSA in Combination with Chemotherapy or Cetuximab and Radiation Therapy for the Treatment of High Risk, Stage III-IVB Head and Neck Squamous Cell Carcinoma

    This phase I / Ib trial studies the side effects and best dose of sEphB4-HSA when given together with chemotherapy or cetuximab and radiation therapy in treating patients with high risk, stage III-IVB head and neck squamous cell carcinoma. sEphB4-HSA works by blocking one way tumors get a blood supply. Chemotherapy drugs, such as cisplatin or carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as cetuximab, may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving sEphB4-HSA with chemotherapy or cetuximab and radiation therapy may work better in treating patients with head and neck squamous cell carcinoma compared to cetuximab and radiation therapy alone.
    Location: University of Colorado, Denver, Colorado

  • Encorafenib, Cetuximab, and Nivolumab in Treating Patients with Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer

    This phase I / II trial studies the best dose and side effects of encorafenib, cetuximab, and nivolumab and how well they work together in treating patients with microsatellite stable, BRAFV600E gene mutated colorectal cancer that cannot be removed by surgery (unresectable) or has spread to other places in the body (metastatic). Encorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as cetuximab, may interfere with the ability of tumor cells to grow and spread. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving encorafenib, cetuximab, and nivolumab may work better in treating patients with colorectal cancer compared to cetuximab alone.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Cetuximab in Treating Patients with Head and Neck Squamous Cell Carcinoma

    This phase II trial studies how well cetuximab works in treating patients with head and neck squamous cell carcinoma. Monoclonal antibodies, such as cetuximab, may interfere with the ability of tumor cells to grow and spread.
    Location: University of Wisconsin Hospital and Clinics, Madison, Wisconsin

  • Porfimer Sodium Interstitial Photodynamic Therapy with or without Standard of Care Chemotherapy in Treating Patients with Locally Advanced or Recurrent Head and Neck Cancer

    This phase I / II trial studies the side effects of interstitial photodynamic therapy and to see how well it works with standard of care chemotherapy in treating patients with head and neck cancer that has spread to other parts of the body (locally advanced) or that has come back (recurrent). Interstitial photodynamic therapy uses a light-sensitive drug called porfimer sodium. This drug is activated by laser light delivered through special fibers into the tumor. It is not yet known how well porfimer sodium interstitial photodynamic therapy works, with or without standard of care chemotherapy, in treating patients with head and neck cancer.
    Location: Roswell Park Cancer Institute, Buffalo, New York

  • Ibrutinib and Cetuximab or Nivolumab in Treating Patients with Recurrent or Metastatic Head and Neck Squamous Cell Cancer

    This phase II trial studies how well ibrutinib works with cetuximab or nivolumab in treating patients with head and neck squamous cell carcinoma that has come back or has spread to other places in the body. Ibrutinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as cetuximab and nivolumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving ibrutinib with cetuximab or nivolumab may work better in treating patients with head and neck cancer.
    Location: University of California San Diego, San Diego, California

  • Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS / NRAS / BRAF / PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status

    This is a phase II trial to examine the efficacy of neratinib plus trastuzumab or neratinib plus cetuximab in patients with "quadruple wild-type" (all RAS / NRAS / BRAF / PIK3CA wild-type), metastatic colorectal cancer based on HER2 status (amplified, non-amplified [wild-type] or mutated). Patients must have confirmed quadruple wild-type (WT) genotype, via NSABP MPR-1 or from colonic biopsy or a metastatic biopsy taken prior to treatment, and known HER2 status.
    Location: 2 locations

  • Palbociclib and Intensity-Modulated Radiation Therapy with Cisplatin or Cetuximab in Treating Patients with Head and Neck Squamous Cell Cancer

    This phase II trial studies how well palbociclib and intensity-modulated radiation therapy with cisplatin or cetuximab works in treating patients with head and neck squamous cell cancer. Palbociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as cetuximab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Intensity-modulation radiation therapy uses varying intensities of radiation beams to kill cancer cells and shrink tumors, thereby reducing the damage to nearby healthy tissue. It is not yet known whether giving palbociclib and intensity-modulated radiation therapy with cisplatin or cetuximab works better at treating head and neck squamous cell cancer.
    Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri

  • Afatinib Dimaleate and Cetuximab as Second-Line Treatment in Treating Patients with Recurrent or Metastatic Head and Neck Squamous Cell Cancer

    This phase II trial studies how well afatinib dimaleate and cetuximab work as second-line treatment in treating patients with head and neck squamous cell cancer that has come back or has spread to other parts of the body. Afatinib dimaleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as cetuximab, may interfere with the ability of tumor cells to grow and spread. Giving afatinib dimaleate and cetuximab may work better in treating patients with head and neck squamous cell cancer.
    Location: Yale University, New Haven, Connecticut

  • Radiation Therapy with Cisplatin or Docetaxel and Cetuximab in Treating Patients with Stage III-IVB Head and Neck Cancer

    This randomized phase II trial studies how well radiation therapy in combination with cisplatin or docetaxel and cetuximab works in treating patients with stage III-IVB head and neck cancer. Radiation therapy uses high energy x rays to kill tumor cells. Docetaxel is designed to stop the growth of cancer cells, which may cause the cells to die. It may also damage blood vessels in tumor tissue. Cetuximab is designed to prevent or slow down the growth of cancer cells by blocking proteins inside the cancer cell, called the epidermal growth factor receptor (EGFR). Cisplatin has a platinum atom at its center. The platinum may poison the cancer cells, which may cause them to die. It is not yet known whether radiation therapy is more effective when given with cisplatin or docetaxel and cetuximab in treating patients with head and neck cancer.
    Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania

  • Bevacizumab and Temsirolimus Alone or in Combination with Valproic Acid or Cetuximab in Treating Patients with Advanced or Metastatic Malignancy or Other Benign Disease

    This phase I trial studies the side effects and best dose of bevacizumab and temsirolimus alone or in combination with valproic acid or cetuximab in treating patients with a malignancy that has spread to other places in the body or other disease that is not cancerous. Immunotherapy with bevacizumab and cetuximab, may induce changes in body’s immune system and may interfere with the ability of tumor cells to grow and spread. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as valproic acid, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether bevacizumab and temsirolimus work better when given alone or with valproic acid or cetuximab in treating patients with a malignancy or other disease that is not cancerous.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients with Metastatic Colorectal Cancer

    This phase I trial studies the best dose and side effects of irinotecan hydrochloride when given with utomilumab and cetuximab in treating patients with colorectal cancer that has spread to other places in the body (metastatic). Monoclonal antibodies, such as utomilumab and cetuximab, may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as irinotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving utomilumab, cetuximab, and irinotecan hydrochloride may work better in treating patients with colorectal cancer.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Stereotactic Radiosurgery and Cetuximab with or without Docetaxel in Treating Patients with Recurrent Head and Neck Cancer Previously Treated with Radiation Therapy

    This randomized phase II trial studies how well stereotactic radiosurgery and cetuximab with docetaxel work compared with stereotactic radiosurgery and cetuximab alone in treating patients with head and neck cancer previously treated with radiation therapy that has come back after a period of improvement (recurrent). Stereotactic radiosurgery, also called stereotactic body radiation therapy (SBRT), uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Cetuximab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving stereotactic radiosurgery and cetuximab with or without docetaxel is more effective in killing tumor cells.
    Location: 2 locations

  • Intratumoral Microdosing of TAK-981 in Head and Neck Cancer

    This is a multi-center, single arm, open-label, multi-agent, localized pharmacodynamic biomarker Phase 0 trial designed to study the biological effects within the tumor microenvironment of TAK-981 and TAK-981 combined with cetuximab or avelumab when administered intratumorally in microdose quantities via the CIVO device. CIVO stands for comparative in vivo oncology.
    Location: 2 locations